26.10.2022 00:00:00
|
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 3, 2022.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and inflammatory diseases as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at https://www.nektar.com.
Contacts:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2022-on-thursday-november-3-2022-after-close-of-us-based-financial-markets-301659191.html
SOURCE Nektar Therapeutics

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
28.02.25 |
NASDAQ Composite Index-Papier Nektar Therapeutics-Aktie: So viel hätten Anleger an einem Nektar Therapeutics-Investment von vor einem Jahr verdient (finanzen.at) | |
26.02.25 |
Börse New York in Grün: NASDAQ Composite zum Handelsende mit grünem Vorzeichen (finanzen.at) | |
25.02.25 |
Angespannte Stimmung in New York: NASDAQ Composite im Minus (finanzen.at) | |
25.02.25 |
Börse New York: NASDAQ Composite notiert am Mittag im Minus (finanzen.at) | |
24.02.25 |
Verluste in New York: NASDAQ Composite schließt im Minus (finanzen.at) | |
24.02.25 |
Verluste in New York: NASDAQ Composite zeigt sich am Mittag schwächer (finanzen.at) | |
21.02.25 |
NASDAQ Composite Index-Wert Nektar Therapeutics-Aktie: So viel Verlust hätte eine Investition in Nektar Therapeutics von vor 10 Jahren bedeutet (finanzen.at) | |
20.02.25 |
Börse New York: NASDAQ Composite zum Start des Donnerstagshandels im Minus (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,75 | -1,76% |
|